Vaccine

Vaccine

Long-acting antibody demonstrates promising efficacy in infant RSV. New real-world evidence from a long-term follow up study adds to evidence of the high efficacy of Beyfortus in infant RSV.

This groundbreaking study showcases the potential of long-acting antibodies in providing protection against respiratory syncytial virus (RSV) in infants. The results highlight the importance of continued research and development in the field of vaccines to combat infectious diseases effectively.